Direkt zum Inhalt | Direkt zur Navigation

Benutzerspezifische Werkzeuge

Sektionen
Studienregister
Sie sind hier: Startseite / Klinische Studien / Studienregister

Studienregister

  • Akute Leukämien (Beschreibung)
  • Allogene Stammzelltransplantation (Beschreibung)
    • Graft-versus-Host-Reaktion (GvHD) (Beschreibung)
      • akute GvHD
        • CSL964_2001_MODULAATE Study (bei GvHD): A Phase 2/3, Multicenter, randOmized, Double-blind, placebo-controlled, stUdy to evaLuate the safety and efficacy of Alpha-1 AntiTrypsin for the prEvention of graft-versushost disease in patients receiving hematopoietic cell transplant (MODULAATE Study)
        • GRAVITAS-301 Studie (INCB39110-301): A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease
        • HERACLES: Treatment of steroid refractory gastro-intestinal acute graft-versus-Host disEase afteR AllogeneiC hematopoietic stem celL transplantation with fEcal microbiota tranSfer
        • JZP963-201: A Phase 2, Prospective, Randomized, Open-label Study on the Efficacy of Defibrotide Added to Standard of Care Immunoprophylaxis for the Prevention of Acute Graft-versus-Host-Disease in Adult and Pediatric Patients After Allogeneic Hematopoietic Stem CellTransplant
      • chronische GvHD
      • Prophylaxe
    • Primärtherapie
      • CSL964_2001_MODULAATE Study (bei GvHD): A Phase 2/3, Multicenter, randOmized, Double-blind, placebo-controlled, stUdy to evaLuate the safety and efficacy of Alpha-1 AntiTrypsin for the prEvention of graft-versushost disease in patients receiving hematopoietic cell transplant (MODULAATE Study)
    • Rezidivtherapie
      • AZALENA 2013: Phase-II trial to assess the efficacy and safety of Lenalidomide in addition to 5-Azacitidine and donor lymphocyte infusions (DLI) for the treatment of patients with MDS, CMML or AML who relapse after allogeneic stem cell transplantation.
  • Chronische lymphatische Leukämien (Beschreibung)
  • Chronisch myeloproliferative Syndrome (Beschreibung)
  • Hodgkin Lymphome (Beschreibung)
  • Non-Hodgkin Lymphome (Beschreibung)
  • Myelodysplastische Syndrome (Beschreibung)
    • AZALENA 2013: Phase-II trial to assess the efficacy and safety of Lenalidomide in addition to 5-Azacitidine and donor lymphocyte infusions (DLI) for the treatment of patients with MDS, CMML or AML who relapse after allogeneic stem cell transplantation.
    • M15-522: A Phase 1b Study Evaluating the Safety, Pharmacokinetics and Efficacy of Venetoclax as a Single-Agent and in Combination with Azacitidine in Subjects with Higher-Risk Myelodysplatic Syndromes after Hypomethyllating Agent-failure
    • M15-531: A Phase 1b Dose Escalation Study Evaluating the Safety and Pharmacokinetics of Venetoclax in Combination with Azacitidine in Subjects with Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)
  • Post-Transplantationslymphoproliferative Erkrankungen (PTLD) (Beschreibung)
  • Sonstige Erkrankungen im Bereich Hämato-Onkologie (Beschreibung)
  • Solide Tumoren (Beschreibung)
  • CAR-T-Zell-Therapie (Beschreibung)
    • CCTL019E2202 Elara: A Phase II, single arm, multicenter open label trial to determine the efficacy and safety of tisagenlecleucel (CTL019) in adult patients with refractory or relapsed follicular lymphoma
    • CCTL019H2301 - BELINDA: Tisagenlecleucel versus standard of care in adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: A randomized, open label, phase III trial (BELINDA)
    • CCTL019J2101 - Portia: Phase Ib study of tisagenlecleucel in combination with pembrolizumab in relapsed/refractory (r/r) Diffuse Large Bcell Lymphoma (DLBCL) patients
    • JCAR017-BCM-001: A Phase 2, Single-Arm, Multi-Cohort, Multi-Center Trial to Determine the Efficacy and Safety of JCAR017 in Adult Subjects with Aggressive B-Cell Non-Hodgkin Lymphoma
    • JCAR017 GC-LTFU-001: Long-Term Follow-up Protocol for Subjects Treated with Gene-Modified T cells
    • KarMMa-3 (BB2121-MM-003): A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Triplet Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)
    • MB-CART2019.1 Lymphoma: A phase I/II safety, dose finding and feasibility trial of MB-CART2019.1 in patients with relapsed or resistant CD20 and CD19 positive B-NHL
    • MB-CART20.1 Lymphoma: A phase I/II safety, dose finding and feasibility trial of MB-CART20.1 in patients with relapsed or resistant CD20 positive B-NHL
    • MB-CART20.1 Melanoma: Multicenter phase I trial of MB-CART20.1 for the treatment of patients with metastatic melanoma
  • Bewegung und Krebs (Beschreibung)
  • Infektiologie (Beschreibung)
  • Tuberkulose (Beschreibung)
  • Immunologie (Beschreibung)
  • Sonstige